E-mail ID : info@iamg.in |
Online Submission |
Click Here For Online Submission |
Instructions for authors |
Genetic Clinics |
Editorial board |
Get Our Newsletter |
Subscribe |
Send Your Feedback |
Feedback Form |
About Us |
IAMG |
Abstract
July-September 2015 | Vol. 8 | Issue 3 | Page No 15-16 | |||
Genome editing technologies: Future of functional andtherapeutic genetics! | |||
Meenal Agarwal | |||
Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow | |||
Address for Correspondence Email: meenal91@gmail.com | |||
Abstract All over the world, the procedure related risk of miscarriage following an invasive prenatal testing is quoted to be 1-2%. Akolekar et al. have performed a meta-analysis of articles available on MEDLINE, EMBASE, CINHAL and Cochrane library in the period between 2000 and 2014.1 The weighted pooled risk was estimated by 324 losses in 42,716 women undergoing amniocentesis and 207 losses in 8,899 women undergoing chorionic villous sampling. The authors concluded that the risk of procedure related risk of miscarriage after amniocentesis is 1:1000 and 1:500 after chorionic villous sampling which is not significantly different from the miscarriage rate in women who have not undergone the invasive testing. These figures can be used for counseling women who opt for invasive prenatal testing and help them in make informed choices. | |||
HTML Full Text | Download PDF |